Amgen (AMGN) : Sarissa Capital Management Lp has sold out all of its stake in Amgen during the most recent quarter, according to the disclosure filed by the company on Aug 15, 2016 with the SEC. The investment management company has sold out 90,000 shares of Amgen which is valued at $15,571,800.
Other Hedge Funds, Including , Highbridge Capital Management reduced its stake in AMGN by selling 2,345 shares or 37.93% in the most recent quarter. The Hedge Fund company now holds 3,837 shares of AMGN which is valued at $663,878. Amgen makes up approx 0.02% of Highbridge Capital Management’s portfolio.Twin Capital Management Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 9,212 additional shares and now holds a total of 64,167 shares of Amgen which is valued at $11,064,316. Amgen makes up approx 0.80% of Twin Capital Management Inc’s portfolio.Rockefeller Financial Services Inc reduced its stake in AMGN by selling 743 shares or 14.32% in the most recent quarter. The Hedge Fund company now holds 4,446 shares of AMGN which is valued at $736,569. Amgen makes up approx 0.01% of Rockefeller Financial Services Inc’s portfolio.
Amgen opened for trading at $170.55 and hit $170.56 on the upside on Thursday, eventually ending the session at $170.13, with a gain of 0.04% or 0.07 points. The heightened volatility saw the trading volume jump to 18,76,141 shares. Company has a market cap of $127,319 M.
On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.
Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.